Seeking Alpha

Theodore Cohen

 
View as an RSS Feed
View Theodore Cohen's Comments BY TICKER:
Latest  |  Highest rated
  • 5 More Stocks That Could Collapse In 2012 [View article]
    LOL They will hit cash-flow breakeven this year.

    Ted
    Feb 27, 2012. 09:22 AM | Likes Like |Link to Comment
  • 5 More Stocks That Could Collapse In 2012 [View article]
    Dendreon Reports Fourth Quarter and 2011 Year End Financial Results
    — Conference Call to be Hosted February 27, 2012 at 9:00 a.m. ET/6:00 a.m. PT —
    SEATTLE--(BUSINESS WIRE)-- February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

    PS

    8:41 AM Dendreon (DNDN): Q4 EPS of $0.45 beats by $0.78. Revenue of $202.1M beats by $81M. Shares +2.9% premarket.

    Have a great day. Ted (;>)
    Feb 27, 2012. 09:03 AM | Likes Like |Link to Comment
  • Dendreon Gains Will Be Short-Lived [View article]
    Dendreon Reports Fourth Quarter and 2011 Year End Financial Results
    — Conference Call to be Hosted February 27, 2012 at 9:00 a.m. ET/6:00 a.m. PT —
    SEATTLE--(BUSINESS WIRE)-- February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

    The net loss for the year ended December 31, 2011 was $337.8 million, or $2.31 per share, compared to $439.5 million, or $3.18 per share for the year ended December 31, 2010. Net income in the fourth quarter of 2011 was $38.1 million or $0.26 per share, compared to a net loss of $91.8 million, or $0.64 per share, for the same period in 2010. The fourth quarter of 2011 included a royalty payment of $125 million associated with the sale of our VICTRELIS™ (boceprevir) royalty interest. Dendreon's total operating expenses, including cost of product revenue, for the year ended December 31, 2011 were $633.3 million compared to $340.2 million in 2010.

    PS

    8:41 AM Dendreon (DNDN): Q4 EPS of $0.45 beats by $0.78. Revenue of $202.1M beats by $81M. Shares +2.9% premarket.

    Have a great day. Ted (;>)
    Feb 27, 2012. 09:00 AM | Likes Like |Link to Comment
  • Vical's Herpes Vaccine Headed To The Clinic [View article]
    Anything's possible. But if the vaccine demonstrates safety and efficacy early, there always is the possibility the FDA might work with the company to move it along more quickly.

    Ted
    Feb 27, 2012. 07:18 AM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    Interesting. Can you cite sources?

    Ted
    Feb 24, 2012. 08:51 AM | Likes Like |Link to Comment
  • 5 More Stocks That Could Collapse In 2012 [View article]
    Bill, Dendreon announced their 4Q2011 results and full-year results for Provenge on January 5, 2012. Here’s the summary:

    Dendreon Announces Fourth Quarter Revenues and Update on Commercialization

    — Company Reports Gross PROVENGE Revenues of Approximately $82M in Q4, Gross PROVENGE Revenues of Approximately $228M in 2011 —

    SEATTLE–(BUSINESS WIRE)– Dendreon Corporation (Nasdaq: DNDN) today announced revenue for the fourth quarter ended December 31, 2011, reporting gross product revenue of approximately $82 million. This represents approximately 25% growth over the third quarter ended September 30, 2011, and approximately 230% growth compared to the fourth quarter ended December 31, 2010. In addition, Dendreon reported full-year gross revenues from PROVENGE® (sipuleucel-T) sales of approximately $228 million.

    http://bit.ly/ABsVLt

    Regarding revenue, one source I have come to trust predicts a gross revenue of $40M for April 2012, which when annualized yields roughly $500M, the cash-flow break even point for the company.

    http://bit.ly/yt19jY

    You are correct...this stock will surprise, but at this point, being 'short' going into the April-May timeframe could be bad for your health.

    Ted
    Feb 23, 2012. 11:18 AM | 6 Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    New time for DNDN CC on Monday:

    SEATTLE--(BUSINESS WIRE)--

    February 22, 2012 – Dendreon Corporation (Nasdaq: DNDN - News) today announced that management will host a conference call on Monday, February 27, 2012, at 9:00 a.m. ET to review fourth quarter and year-end financial results. This conference call was previously scheduled at 4:30 p.m. ET on the same date.

    Access to the discussion may be obtained as follows:

    Time: 9:00 a.m. ET / 6:00 a.m. PT
    Date: February 27, 2012
    Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international);
    conference pass code: 46511476
    Webcast: http://www.dendreon.com (homepage and investor relations section)


    A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 46511476. The replay will be available from 12:00 p.m. ET on Monday, February 27, until 11:59 p.m. ET on Monday, March 5. In addition, the webcast will be archived for on-demand listening for 90 days at http://www.dendreon.com.

    In addition, Dendreon Corporation also announced that management will present at the following conferences:

    •RBC Capital Markets’ Healthcare Conference in New York City, on February 28, 2012, at 3:35 p.m. ET
    •Citi 2012 Global Healthcare Conference in New York City, on February 29, 2012, at 2:00 p.m. ET
    The presentations will be audio webcast live and available for replay from Dendreon’s website, http://www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replays, go to the Investor Relations section of the website.

    About Dendreon

    Dendreon Corporation is a biotechnology company whose mission is to target
    Feb 22, 2012. 08:05 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    The logistics involved in overseas air travel are simply too complex and time-consuming. Even the slightest weather problems turns the East Coast airspace into a disaster. Better a facility in Germany, for example, with ready access to all of Western Europe.

    They'll work it out. I'm more concerned that they recognize how complex it will be to sell into the individual countries, and move quickly to bring an EU marketing partner onboard. Approval to sell within the EU is one thing, but then, each country must be tackled individually.

    Ted
    Feb 22, 2012. 05:27 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    It's difficult to get a handle as to what is going on. Provider sites now number close to 1,000, if not slightly more than that, with the growth, of course, coming in the community sector. By now, those who have been through 2 or 3 reimbursement cycles should feel confortable enough to prescribe more frequently, which is the source, of course, of Schiffman's sanguine outlook for a major uptake in usage during 2Q12. I still believe we will see $40M in monthly revenue in May, 2012, at the latest, which annualized is $500M and cash-flow breakeven.

    That said, EU will be a tough nut to crack, given the poor state of the economies in the Union and the pricing pressures Provenge will face. There also are uncertainties regarding how they will produce and market in the EU. That said, I am much more optimistic now, with Johnson at the helm, that the move into Europe will be accelerated and that solutions will be found to whatever pricing issues are encountered in the various countries.
    Feb 22, 2012. 03:26 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    Yes, and note that they have a new analyst covering Dendreon. Looks like they are positioning themselves to address whatever they learn on Monday, the 27th,* at the conference call without the baggage of their past positions.

    Thanks.

    Ted

    *Dendreon to Host Conference Call on February 27 to Announce Fourth Quarter and Year-End Financial Results and Webcast Presentations at Upcoming Conferences

    SEATTLE--(BUSINESS WIRE)-- February 1, 2012 — Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 27, 2012, at 4:30 p.m. ET to review fourth quarter and year-end financial results.

    Access to the discussion may be obtained as follows:

    Time: 4:30 p.m. ET / 1:30 p.m. PT
    Date: February 27, 2012
    Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international);
    conference pass code: 46511476
    Webcast: http://www.dendreon.com (homepage and investor relations section)

    http://bit.ly/wbfNkQ
    Feb 22, 2012. 09:26 AM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    Thanks, slowtime.

    Controversial subjects always brings out a crowd. It makes life interesting.

    Have a great evening.

    Ted
    Feb 21, 2012. 05:21 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    Ah, yes...many thanks. So many games of musical chairs being played following the 2008 financial collapse that you need a scorecard to keep track of the players. (;>)

    Ted
    Feb 21, 2012. 04:00 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    Who or what is SBMS? A simple Google search doesn't readily reveal their identity?

    Best to put quote marks around material to separate text taken from the literature from your comments. Thanks, WW.

    Ted
    Feb 21, 2012. 03:29 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    That's why medicine is, to a large extent, still more an art than a science. If everything were known, positive-definite, physicians wouldn't be scratching their heads so much when you see them with your aches and pains.

    That said, and with all due respect to the 'expert' you cited, he might want to take a moment and review the current literature. In particular, the Journal of Clinical Oncology had this to say about sequencing:

    "The practical dilemma of the appropriate sequence of use of the two new noncytotoxic agents (sipuleucel-T and abiraterone) is being addressed by trials that are under development. For now, given the broader window of applicability of abiraterone and the longer time required to develop an immune response with sipuleucel-T, if both agents are to be used, it seems reasonable to administer sipuleucel-T first with Abiraterone after additional disease progression. Biomarkers to help define the optimal use of immunotherapy are needed."

    http://bit.ly/oWIylJ

    And if he is of a mind to, for example, jump the gun and give Zytiga first (off label in Provenge's space, and with prednisone, mind you), consider this:

    In the asymptomatic/minimally symptomatic mCRPC setting for which Provenge is indicated, the National Comprehensive Cancer Network, or NCCN (NCCN; log-in required), has given Provenge a category 1 rating, the highest evidence level recommendation based upon its three Phase III clinical trials. By contrast, and in Provenge’s "space" - the asymptomatic/minimally symptomatic mCRPC setting - Zytiga has a category 2B rating, the second lowest rating, based upon small single arm Phase II trials. This has not stopped some physicians from prescribing Zytiga off-label to PCa sufferers in an estimated 22% of cases where patients probably should be treated with Provenge first. Current thinking is that prescribing Zytiga first will delay medication with Provenge. The reason for this stems from the belief that if Zytiga is given first, a patient’s system must first be cleansed of prednisone before Provenge can be given, something that can take at least 60 days.

    What all this 'goes to show you' is that YOU are the most important advocate of your own health care, and simply going in blind and trusting the word of your physician may or may NOT result in your receiving the optimal care for what is ailing you.

    Not to put too fine a point on it: trust but verify!

    Ted
    Feb 21, 2012. 02:56 PM | 1 Like Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    The FDA says Provenge works. That's good enough for me.

    Ted
    Feb 21, 2012. 10:54 AM | Likes Like |Link to Comment
COMMENTS STATS
1,903 Comments
1,420 Likes